Malaria Vaccine Implementation Programme Framework for Policy Decision
|
|
- Claude Hunt
- 5 years ago
- Views:
Transcription
1 Malaria Vaccine Implementation Programme Framework for Policy Decision Mary J Hamel, IVR SAGE 17 April
2 Questions for SAGE on the Framework for Policy Decision 1. Does SAGE agree with the approach? 2. Are the suggested outcomes and matrices useful for policy decision? 3. Does SAGE agree on the suggested next steps? 2
3 Framework for Policy Decision for RTS,S MPAC and SAGE requested data be collected through the pilot implementations to answer questions on feasibility, safety, impact to inform a policy decision on wider use of RTS,S Framework for Policy Decision aims to describe how data will inform policy at the end of the pilots, in 2022 Also will describe how data could inform 1. Expansion of vaccinations into pilot comparator areas 2. Broader country-wide implementation prior to should emerging findings show: Concerns about safety resolved Implementation data favorable Fourth dose coverage high 3 1. JTEG Background Paper on the RTS,S/AS01 Malaria Vaccine, Sep 2015
4 Overview of MVIP timelines: Data accumulating over time Phase 1 Phase Ongoing review of MVIP data and regular updates to SAGE/MPAC??? Vaccine implementation Safety data Sentinel hospital surveillance Routine pharmacovigilance Joint regulatory review Authorization decision RTS,S launch GSK EPI MAL 002 pharmacovigilance baseline study 4 th dose for first children Potential policy recommendation Accumulating info GSK EPI MAL 003 Phase 4 study on safety, effectiveness, impact Feasibility data Administrative data monitoring Household surveys Qualitative longitudinal study Baseline Coverage of dose 1-3 Coverage of dose 4 Indicates 3 rd country New vaccine post-introduction evaluation Health economic assessments PIE Vaccine delivery cost analysis Budget impact analysis Impact data Community-based mortality surveillance Sentinel 4 hospital surveillance Impact on severe malaria Impact on mortality
5 Benefits of Developing a Framework for Policy Decision SAGE and MPAC members will refine ideas on the relative contribution of the collected data (feasibility, safety, impact) to a future policy recommendation Provide clarity on the expected use of the data in anticipation of potential changes in SAGE membership between the time the SAGE/MPAC recommendations were made and the programme end (2022) Funders, potential funders, and manufacturers can refer to the framework for planning purposes Reducing the likelihood of gaps in funding or vaccine availability should the vaccine be recommended for broader use 5
6 Questions to be Considered for the Framework for Policy Decision What criteria, if met, would likely lead to a recommendation for vaccine use at the end of the pilot programme What to do if conflicting findings from different countries Or if data availability lags considerably from one country What criteria, if met, would likely lead to a recommendation not to implement the vaccine Is it conceivable that there could be an earlier policy recommendation, prior to pilot end If yes, what data would support such a decision 6
7 Questions to be Considered for the Framework for Policy Decision: Broader Implementation Before Study End What findings would support or delay expansion into the pilot comparator areas What criteria would support favorable implementation data, and broader country-wide implementation of RTS,S High coverage dose 4, safety signals resolved and: No or little adverse effect on other vaccines? Continued use of malaria interventions, or impact data suggesting no negative effect of reduced use? Cost effectiveness? What would be considered high fourth dose coverage Can thresholds of vaccine coverage that predict impact and other criteria be considered a priori and be used to guide decisions on country-wide expansion of vaccine use before pilot end 7
8 Criteria e.g vaccine coverage MVIP Framework for Decision Making Recommendation for broader use Very Likely e.g. high (?>X%) coverage of doses 1 4, safety concerns resolved Need for nuanced discussion Recommendation for broader use Very Unlikely e.g. poor (<X%) coverage of doses 1 3, <Y% coverage dose 4 or major safety concern 8
9 Modelers Engaged to Estimate Thresholds of Vaccine Coverage that Predict Impact Through PATH, engaged modellers from Swiss Tropical Institute and Imperial College, London Generating estimates for a range of vaccine coverage that will estimate impact on severe malaria, malaria mortality or cost effectiveness Modelling methods presented to the WHO Immunization and Vaccine-related Implementation Research Advisory Committee (IVIR-AC) March
10 Modelers will Consider Two Scenarios for Vaccine Impact and Cost-effectiveness (CE) Estimates 1. Impact estimates for MVIP pilot areas: a. Estimates of impact and CE will be generated with parasite prevalence that correspond to those in the pilot areas b. Area-specific assumptions on vaccination coverage, costs, and coverage of malaria preventive/curative interventions based on publicly available data 2. Impact estimates for a range of malaria transmission settings where the RTS,S vaccine may be recommended/implemented should there be a policy recommendation: a. Estimates will be generated for parasite prevalence levels representative of those found in sub-saharan Africa (e.g. 10% to 65%) b. A common set of assumptions on vaccination coverage, costs, and coverage of malaria preventive and curative interventions will be applied to all transmission settings based on publically available data 10
11 Outcomes and Outcome Metrics to be Generated Outcomes: Severe malaria cases averted Severe hospitalized malaria averted Malaria deaths averted DALYs averted Outcome metrics: Events averted per 100,000 vaccinated Events averted per dose Events averted per 100,000 population 0-5 year olds; target age group Percent reduction in events Cost per event averted 11
12 Illustrative Example of Outputs: Events Averted by Malaria Transmission (not based on actual estimates) Figure 1: Events averted per 100,000 population for a single vaccine coverage scenario, across a range of transmission settings. This figure can be produced for specific population groups and vaccine coverage scenarios, and 95% credible intervals can be included. 12
13 Illustrative Example of Output: Events Averted by Dose 4 Coverage (not based on actual estimates) Figure 2: Events averted per 100,000 population for a single transmission setting, across a range of scenarios for coverage of the fourth vaccine dose. In this example, the coverage of the third dose is fixed, and the fourth dose coverage varies along the X-axis. This figure can be produced for specific population groups and transmission settings (for example in a series of plots for PfPR 2-10 = 10 40%) and different levels of coverage of the first three vaccine doses. 13
14 Illustrative Examples of Outputs: Cost Per Event Averted (not based on actual estimates) Figure 4: Cost per event averted for a range of transmission settings, for three vaccine coverage scenarios, where coverage of doses 1 3 and dose 4 are both varied. A range of different vaccine coverage assumptions can be included. 14
15 Timeline Timelines and Activities for Framework Activity 1Q-2Q 2018 Seeking input on the Framework for Policy Decision (Presented to the IVIR-AC in March 2018, PAG March 2018, SAGE/MPAC April 2018) 2Q-3Q 2018 Modelers will generate estimates for inclusion in the Framework for Policy Decision (Presentation to IVIR-AC September 2018), modelled estimates of criteria thresholds to be incorporated into the Framework Convene working group, including members from PAG and MPAC/SAGE, to deliberate on Framework Present the working group s report and recommendations on the Framework to PAG, SAGE and MPAC for discussion in fall 2018 or spring
16 Questions for SAGE on the Framework for Policy Decision 1. Does SAGE agree with the approach? 2. Are the suggested outcomes and matrices useful for policy decision? 3. Does SAGE agree on the following suggested next steps? I. Additional SAGE and MPAC members join the PAG working group to consider and deliberate on the questions posed within the Framework (~2 from each?) II. III. The working group report back with those considerations and presents to PAG, MPAC and SAGE at future meeting, aiming for fall 2018 or spring 2019 Next step for Chairs of SAGE and MPAC to provide to the MVIP secretariat the names of those available to participate on such a working group 16
17 17 Thank you
18 18 Extra slides
19 Summary of IVIR-AC informal feedback Produce multiple outcome metrics for each outcome. Some examples include events averted per 100,000 vaccinated children, events averted per dose, events averted per 100,000 population (all ages or 0-5 year olds). Present impact results for 3 doses vs. no vaccination Present impact results for 4 doses vs. no vaccination, where 3 rd and 4 th dose coverage is the same. Present impact results for multiple levels of 4 th dose coverage for a given 3 rd dose vaccine coverage. This will assess the incremental impact of differing vaccine coverage for the 4 th dose. Once formal feedback from the IVIR-AC is received, it will be incorporated into the modeling plans as appropriate. 19
20 Vaccine coverage assumptions (Example) Scenario Dose 1 coverage 1 (10% drop-off between 1-3, 20% drop-off between 3 and 4) 2 (10% drop-off between 1-3, 10% drop-off between 3 and 4) 3 (5% drop-off between 1-3, 20% drop-off between 3 and 4) 4 (5% drop-off between 1-3, 10% drop-off between 3 and 4) 5 (5% drop-off between 1-3, 5% drop-off 20 between 3 and 4) Dose 2 dropout rate Dose 3 dropout rate Cumulative coverage doses 1-3 Dose 4 dropout rate Cumulative coverage doses % 10% 10% 41% 20% 32% 60% 10% 10% 49% 20% 39% 70% 10% 10% 57% 20% 45% 80% 10% 10% 65% 20% 52% 90% 10% 10% 73% 20% 58% 50% 10% 10% 41% 10% 36% 60% 10% 10% 49% 10% 44% 70% 10% 10% 57% 10% 51% 80% 10% 10% 65% 10% 58% 90% 10% 10% 73% 10% 66% 50% 5% 5% 45% 20% 36% 60% 5% 5% 54% 20% 43% 70% 5% 5% 63% 20% 51% 80% 5% 5% 72% 20% 58% 90% 5% 5% 81% 20% 65% 50% 5% 5% 45% 10% 41% 60% 5% 5% 54% 10% 49% 70% 5% 5% 63% 10% 57% 80% 5% 5% 72% 10% 65% 90% 5% 5% 81% 10% 73% 50% 5% 5% 45% 5% 43% 60% 5% 5% 54% 5% 51% 70% 5% 5% 63% 5% 60% 80% 5% 5% 72% 5% 69%
21 21
22 Why Develop a Framework for Policy Decision? Provides the opportunity for SAGE and MPAC members to refine ideas on the relative contribution of the collected data (feasibility, safety, impact) to a future policy recommendation Provide clarity on the expected use of the data in anticipation of potential changes in SAGE and MPAC membership between the time the SAGE/MPAC recommendations were made (2015) and the programme end (2022) Funders, potential funders, and manufacturers can refer to the framework for planning purposes Reducing the likelihood of gaps in funding or vaccine availability should the vaccine be recommended for broader use 22
23 Illustrative Examples of Outputs: Varied Coverage of Dose 3, 4 (not based on actual estimates) A. B. Total population Under 5s 23 Figure 3: Percentage reduction of event averted by coverage at 3 rd and 4 th doses for a given PfPr 2-10 by total population (A) and among 0-5 year olds (B), following 5 years of RTS,S implementation. This figure can be produced for multiple populations including number of children vaccinated.
Malaria Vaccine Implementation Programme (MVIP) update and framework for policy decision. Mary J Hamel, WHO MPAC, 11 April 2018
Malaria Vaccine Implementation Programme (MVIP) update and framework for policy decision Mary J Hamel, WHO MPAC, 11 April 2018 MVIP update Background to MVIP MVIP Updates Regulatory Vaccine introduction
More informationOverview of the Malaria Vaccine Implementation Programme (MVIP) Prof. Fred Were SAGE meeting 17 April, 2018
Overview of the Malaria Vaccine Implementation Programme (MVIP) Prof. Fred Were SAGE meeting 17 April, 2018 1 Objectives Brief review Background EMA positive opinion and WHO recommendations Funding Description
More informationRTS,S Malaria Vaccine Implementation Programme A joint initiative of GMP & IVB
RTS,S Malaria Vaccine Implementation Programme A joint initiative of GMP & IVB Update to the Malaria Policy Advisory Committee David Schellenberg, Scientific Advisor, GMP Mary Hamel, Coordinator MVIP,
More informationMALARIA VACCINE PILOTS
MALARIA VACCINE PILOTS BOARD MEETING Judith Kallenberg, Geneva Reach every child www.gavi.org Developments since 2013 (1/5) 2013 Malaria vaccine shortlisted in Vaccine Investment Strategy Board decision
More informationGavi s Vaccine Investment Strategy
Gavi s Vaccine Investment Strategy Judith Kallenberg, Head of Policy WHO Product Development for Vaccines Advisory Committee Meeting Geneva, Switzerland, 7-9 September 2015 www.gavi.org Vaccine Investment
More informationBRIEFING ON RTS,S/AS01 MALARIA VACCINE FOR THE SEPTEMBER 2012 MEETING OF MPAC
BRIEFING ON RTS,S/AS01 MALARIA VACCINE FOR THE SEPTEMBER 2012 MEETING OF MPAC Introduction Date: 12 August 2012. Author: WHO Secretariat with input from JTEG Chair The most advanced vaccine candidate against
More informationReport to the Board June 2016
Report to the Board 22-23 June 2016 SUBJECT: Reviewed by: MALARIA VACCINE PILOTS Programme and Policy Committee Agenda item: 09 - Appendices 1 & 2 Category: For Decision Strategic goal: SG1 - Underused
More informationJTEG s RTS,S/AS01Candidate Policy Recommendations
JTEG s RTS,S/AS01Candidate Policy Recommendations Peter Smith On behalf of the Joint Technical Expert Group JTEG Candidate Policy Recommendations Introductory remark: There is a need to evaluate pilot
More informationSummary of the Meeting of the Strategic Advisory Group of Experts on immunization, April 2018
Summary of the Meeting of the Strategic Advisory Group of Experts on immunization, 17-18 April 2018 The Strategic Advisory Group of Experts (SAGE) on Immunization 1 met on 17 18 April 2018. This full report
More informationMalaria. Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania
Malaria Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania Despite 42% reduction since 2000, a child dies every minute in Africa from malaria 207 million malaria cases in 2012,
More informationMalaria Burden Estimation Evidence Review Group (MBE-ERG)
Malaria Burden Estimation Evidence Review Group (MBE-ERG) Peter Smith - Chair MBE-ERG (with thanks to Kathryn Andrews for drafting slides) MPAC meeting 13 th March, 2013 MBE-ERG: Terms of Reference To
More informationUpdating the Malaria Vaccine Technology Roadmap
Updating the Malaria Vaccine Technology Roadmap Vasee Moorthy MRCP PhD MPAC 14 March 2013 Purpose of this MPAC session MPAC to be updated on the strategic R&D framework for malaria vaccines, including
More informationMark Jit 1,2 1. Improving health worldwide. London School of Hygiene & Tropical Medicine 2. Modelling and Economics Unit, Public Health England
Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, Geneva, 17-18 April 2018 Full public health value proposition of vaccines (FPHVPs) Global economic investment case for vaccines
More informationTYPHOID CONJUGATE VACCINE SUPPORT WINDOW
TYPHOID CONJUGATE VACCINE SUPPORT WINDOW BOARD MEETING Michael F Thomas 29-30 November 2017, Vientiane, Lao PDR Reach every child www.gavi.org Agenda 1 2 3 4 5 Why TCVs? Historical decisions and update
More informationReport to the Board 6-7 June 2018
6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment
More informationGlobal Advisory Committee on Vaccine Safety (GACVS) Report from the June 2017 meeting
Global Advisory Committee on Vaccine Safety (GACVS) Report from the June 2017 meeting Topics discussed in June Safety monitoring of the RTS,S vaccine pilot implementation programme Safety update of BCG
More informationJTEG s Summary of RTS,S/ AS01 Clinical Trial Data
JTEG s Summary of RTS,S/ AS01 Clinical Trial Data Peter Smith On behalf of the Joint Technical Expert Group (JTEG) based on Cohen et al 2010 RTS,S/AS01 Malaria Vaccine l Based on large segment of P. falciparum
More informationEstimating impact and cost-effectiveness of ending cholera roadmap
Estimating impact and cost-effectiveness of ending cholera roadmap Vittal Mogasale International Vaccine Institute, Seoul, South Korea 5 th Annual meeting of GTFCC, 13-14 June Les Pensieres, Veyrier du
More informationReport of the Immunization Practices Advisory Committee (IPAC) to SAGE. Dr Christopher Morgan, IPAC Chair October 2015
Report of the Immunization Practices Advisory Committee (IPAC) to SAGE Dr Christopher Morgan, IPAC Chair October 2015 IPAC Meeting: 14-15 October, 2015 v Standing reports Programmatic Suitability for Prequalification
More informationPapillomavirus Rapid Interface for Modelling and Economics Tool. User Manual
Papillomavirus Rapid Interface for Modelling and Economics Tool User Manual List of abbreviations DALYs disability adjusted life years GDP HPV IARC gross domestic product human papillomavirus International
More informationThe Johns Hopkins Vaccine Initiative Johns Hopkins Bloomberg School of Public Health
WHO Internships (Terms of Reference) for VIEW Scholars Program January 2010 A. Examining approaches to collecting and analyzing HPV vaccine coverage data B. County level burden of disease estimates for
More informationWHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES
WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES SURVEY QUESTIONNAIRE A.1. Introduction The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 as a ten year initiative to address the anticipated
More informationMonitoring and Evaluation Reference Group (MERG) GUIDANCE NOTE
BACKGROUND Monitoring and Evaluation Reference Group (MERG) GUIDANCE NOTE Assessing the Impact of Malaria Control Activities on Mortality among African Children Under 5 Years of Age The Roll Back Malaria
More informationA framework for malaria elimination
A framework for malaria elimination What s new? Dr Pedro Alonso, GMP Director Rationale for new malaria elimination framework The malaria landscape has changed dramatically since 2007 - Increased funding
More informationPlan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 4: READINESS ASSESSMENT
4 Plan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 4: READINESS ASSESSMENT About this toolkit WHAT IS THE PURPOSE AND CONTENTS OF THIS TOOLKIT? This toolkit was developed and used by the OPTIONS
More informationRoadmaps as a Vehicle for Addressing Large- Scale Public Health Challenges: Lessons from the Malaria Vaccine Technology Roadmap
Background to development of vaccine roadmaps, to include priority areas for research, product development, capacities, and policy and commercialization Roadmaps as a Vehicle for Addressing Large- Scale
More informationCopenhagen, Denmark, September August Malaria
Regional Committee for Europe 64th session EUR/RC64/Inf.Doc./5 Copenhagen, Denmark, 15 18 September 2014 21 August 2014 140602 Provisional agenda item 3 ORIGINAL: ENGLISH Malaria Following the support
More informationImplementation of the CFS Evaluation Recommendations 1 and 2 Comments by PSM (24 January 2018)
Implementation of the CFS Evaluation Recommendations 1 and 2 Comments by PSM (24 January 2018) Clarification of what CFS seeks to achieve, how and by whom 1. Does the results chain reflect the results
More informationAnalysis of the demand for a malaria vaccine: outcome of a consultative study in eight countries
Briefing Document: National decision-making framework for malaria vaccines Analysis of the demand for a malaria vaccine: outcome of a consultative study in eight countries This is one of seven briefing
More informationLiving Evidence Network
Living Evidence Network Governance Structure Adopted July 2018 Trusted evidence. Informed decisions. Better health. Living Evidence Network: Governance Structure 2 Contents Background 3 About the Living
More informationFrom Vaccine Development to Policy: A Brief Review of WHO Vaccine-Related Activities and Advisory Processes (2017)
1. Introduction From Vaccine Development to Policy: A Brief Review of WHO Vaccine-Related Activities and Advisory Processes (2017) To help achieve the implementation of the Global Vaccine Action Plan (GVAP),
More informationEvidence Review Group (ERG) on malaria elimination
Evidence Review Group (ERG) on malaria elimination Dr Richard Steketee, ERG chair MPAC meeting - Geneva, 14 September 2016 Rationale for an ERG on malaria elimination The malaria landscape has changed
More informationMedia centre Malaria. Key facts. Symptoms
Media centre Malaria Fact sheet Updated November 2017 Key facts Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes.
More informationWHO Consultation on universal access to core malaria interventions in high burden countries: main conclusions and recommendations
WHO Consultation on universal access to core malaria interventions in high burden countries: main conclusions and recommendations 12-15 February 2018 Salle XI, ILO Building, Geneva, Switzerland Country
More informationGlobal Vaccine Safety Initiative Portfolio activities
Global Vaccine Safety Initiative Portfolio activities 2012-2020 Safety and Vigilance (SAV) Health Systems and Innovation (HIS) World Health Organization Geneva, Switzerland October 2013 ii Table of Contents
More informationMeasuring the path toward malaria elimination
Measuring the path toward malaria elimination Rigorous and achievable targets and milestones can be developed from standard malaria surveillance data. By Thomas S. Churcher, 1 Justin M. Cohen, 2 Joseph
More informationKey points and Q&A. A framework for malaria elimination (2017) Global Malaria Programme. Rationale for updated guidance.
Global Malaria Programme technical guidance Key points and Q&A A framework for malaria elimination (2017) This framework provides guidance on the tools, activities and strategies required to achieve malaria
More informationMeeting of the Strategic Advisory Group of Experts on Immunization (SAGE) October 20-22, 2015 Conclusions and Recommendations
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) October 20-22, 2015 Conclusions and Recommendations Published in the Weekly Epidemiological Record on 11 December, 2015 http://
More informationA framework for malaria elimination. Dr Pedro Alonso, GMP Director
A framework for malaria elimination Dr Pedro Alonso, GMP Director Rationale for new elimination framework The malaria landscape has changed dramatically since 2007 Increased funding Large-scale implementation
More informationStatus of RTS,S/AS01 malaria vaccine candidate
Status of RTS,S/AS01 malaria vaccine candidate Multi-center RTS,S malaria vaccine efficacy trial Phase 3, randomized, controlled, double-blind trial conducted in 11 centers in 7 African countries 15,460
More informationComparison of the cost effectiveness of LLINs, SMC, the RTS,S vaccine and RTS,S plus IPTi in African settings.
Comparison of the cost effectiveness of LLINs, SMC, the RTS,S vaccine and RTS,S plus IPTi in African settings. MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology,
More informationSummary of WHO Position on Rotavirus. Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India)
Summary of WHO Position on Rotavirus Narendra K. Arora SAGE Member Executive Director The INCLEN Trust International New Delhi (India) Presentation WHO Position Papers on Rotavirus Optimizing immunization
More informationGlobal call for action to ensure universal access to malaria diagnosis and treatment
Global call for action to ensure universal access to malaria diagnosis and treatment Joint activity of SEE Team and PDT Unit Andrea Bosman and Richard Cibulskis Outline of the presentation Background Objectives
More informationOverall presentation of IVR Strategy
Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research
More informationSTRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL ( ) POLICY BRIEF
PROGRAMME NATIONAL DE LUTTE CONTRE LES HEPATITES STRATEGIC PLAN AGAINST VIRAL HEPATITIS IN SENEGAL (2019-2023) POLICY BRIEF 1 INVESTING IN THE FIGHT AGAINST HEPATITIS B AND C IN SENEGAL NATIONAL STRATEGIC
More informationHIV Planning: From Guidance to Implementation. Joan Llanes Assistant Program Manager Division of Community Advancement and Leadership Strategies
HIV Planning: From Guidance to Implementation Joan Llanes Assistant Program Manager Division of Community Advancement and Leadership Strategies Overview HIV Planning Guidance Implementing HIV Planning
More informationKenya s experience in Influenza Vaccination Policy Development
Kenya s experience in Influenza Vaccination Policy Development Gideon Emukule Antananarivo, Madagascar, March 20th, 2018 3/28/2018 1 Influenza Vaccination Policy CoAg In Sep 2013, the Kenya MoH and CDC
More informationCost-effectiveness Analysis for HHS
Cost-effectiveness Analysis for HHS Edward Broughton, PhD., MPH Director of Research and Evaluation, USAID ASSIST Project, University Research Co., LLC Ukraine: 1 Mali: 1 Nigeria: 1 2 Uganda: 6 Burundi:
More informationCancer Control Council Evaluation and Monitoring Framework
Cancer Control Council Evaluation and Monitoring Framework Table of contents 1. Purpose...1 2. Background...1 3. Clarification of key tasks...2 4. International evaluation and monitoring frameworks...3
More informationReport to the Board 6-7 June 2018
Report to the Board 6-7 June 2018 SUBJECT: Category: PROGRAMME AND POLICY COMMITTEE CHAIR REPORT For Information Section A: Introduction This report provides the Board with an overview of the activities
More informationData inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov
Data inputs for HIV models and how they inform HIV prevention interventions Dobromir Dimitrov Vaccine & Infectious Disease Division Fred Hutchinson Cancer Research Center Dynamic model integration The
More informationAdvancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction
Advancing RSV maternal immunization: A gap analysis brief An analysis to identify needs for vaccine decision-making and introduction Despite significant advances in child survival, deaths in the earliest
More informationIMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION
IMPACT OF HPV IMMUNIZATION STRATEGIES & POTENTIAL FOR CERVICAL CANCER ELIMINATION Marc Brisson Full Professor Université Laval, Canada SAGE meeting October 24, 2018 Geneva 1 Questions A. What is the potential
More informationNICE Guidelines for HTA Issues of Controversy
NICE Guidelines for HTA Issues of Controversy Mark Sculpher, PhD Professor of Health Economics University of York, UK LMI, Medicines Agency in Norway and the Norwegian Knowledge Centre for the Health Services:
More informationAppendix F. Results of the Electronic Survey of World Bank Task Team Leaders
Appendix F. Results of the Electronic Survey of World Bank Task Team Leaders 1. An electronic survey was administered in April-May 2013 to 112 World Bank Task Team Leaders of Bank-supported health projects
More informationInvesting for a Malaria-Free World
Investing for a Malaria-Free World Recent years have seen extraordinary advances in the fight against malaria, but the gains are fragile and unevenly distributed. Victory against the malaria parasite would
More informationTying it all together health economic modeling
Tying it all together health economic modeling Ruanne V Barnabas, MD, DPhil Associate Professor, Global Health, Allergy & Infectious Disease University of Washington How models can be used with cost-effectiveness
More informationINVESTING FOR A MALARIA-FREE WORLD
INVESTING FOR A MALARIA-FREE WORLD Recent years have seen extraordinary advances in the fight against malaria, but the gains are fragile and unevenly distributed. Victory against the malaria parasite would
More informationNavigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) Module 5. Can my country afford a JE vaccination program?
Navigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) 5 Module 5 Can my country afford a JE vaccination program? about this guide Japanese encephalitis (JE), a viral infection
More informationVC TEG updates for MPAC Meeting, March 2013
VC TEG updates for MPAC Meeting, March 2013 Outline Call to establish a malaria vector control Technical Expert Group (TEG) Process to constitute the Technical Expert Group What are the immediate issues
More informationStrategy to move from accelerated burden reduction to malaria elimination in the GMS by 2030
Strategy to move from accelerated burden reduction to malaria elimination in the GMS by 2030 Dr Walter M Kazadi Coordinator Regional Hub Emergency Response to Artemisinin Resistance Regional Hub GMS MMV
More informationKey Messages for World Malaria Day 2009
INFORMATION RBM/WG/2009/INF.12 10 APR 2009 Draft document General distribution English Only Key Messages for World Malaria Day 2009 Counting Malaria Out to Reaching the 2010 Targets On the occasion of
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More informationReducing malaria in Solomon Islands: lessons for effective aid
Reducing malaria in Solomon Islands: lessons for effective aid Executive Summary Camilla Burkot and Katherine Gilbert The burden of malaria in Solomon Islands, a small island state of approximately 653,500
More informationPolio post-certification strategy
1 Polio post-certification strategy SAGE Meeting, Geneva, 17 April 2018 Michel Zaffran, Director, Polio Eradication, WHO On Behalf o the GPEI Polio Eradication and Endgame Strategy 1. Poliovirus detection
More informationProgramme Malaria integration of new tools for zero deaths and elimination Monday 20 Wednesday 22 February 2012 WP1141
Programme Malaria integration of new tools for zero deaths and elimination Monday 20 Wednesday 22 February 2012 WP1141 Around 40% of the world s population are at risk from malaria and there are approximately
More informationStudy population Pregnant HIV-infected women living in rural areas in resource-poor settings.
Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity Wilkinson D, Floyd K, Gilks C F Record Status This
More informationInvesting for Impact
Global Fund Strategic Framework: Investing for Impact M&E: Capturing data to improve services Workshop to Scale Up the Implementation of Collaborative TB/HIV Activities in Africa 10-11 April, 2013; Maputo,
More informationCalifornia Environmental Protection Agency
California Environmental Protection Agency OCTOBER 2004 ENVIRONMENTAL JUSTICE ACTION PLAN TABLE OF CONTENTS 1. INTRODUCTION...2 1.1 Purpose... 2 1.2 Development and Update...3 2. OBJECTIVES...4 2.1 Develop
More informationTechnical Guidance Note for Global Fund HIV Proposals
Technical Guidance Note for Global Fund HIV Proposals UNAIDS I World Health Organization I August 2011 Rationale for including pharmacovigilance in the proposal Pharmacovigilance is the science and activities
More informationUNICEF ZIKA Diagnostics VACCINES Demand Forecast. Jorgen Kofoed UNICEF SD
UNICEF ZIKA Diagnostics VACCINES Demand Forecast Jorgen Kofoed UNICEF SD 1 Forecasting model: Overview Assesses various methodologies and targeting assumptions Applies 10-year time horizon incorporating
More informationGlobal Report to MPAC: Sustaining the gains in malaria control and elimination. World Malaria Report Objectives
Global Report to MPAC: Sustaining the gains in malaria control and elimination Malaria Policy Advisory Committee Inaugural Meeting Geneva, Switzerland 31 January 2012 Robert D. Newman, MD, MPH Director,
More informationNeed for improved post-marketing surveillance in receiving countries and suggestions on how to monitor safety of newly introduced vaccines
Need for improved post-marketing surveillance in receiving countries and suggestions on how to monitor safety of newly introduced vaccines Patrick Zuber - WHO Meeting with vaccine manufacturers 5 April
More informationBMGF MALARIA STRATEGY TO 2020
BMGF MALARIA STRATEGY TO 2020 Supporting the Drive to Elimination in Mesoamerica & Hispaniola Diana Measham, DrPH, MSc Lead Eliminate Initiative September 25, 2014 The world has three potential future
More informationStakeholder Dissemination Meeting: Total Systems Effectiveness (TSE) Pilot Project in Thailand
Stakeholder Dissemination Meeting: Total Systems Effectiveness (TSE) Pilot Project in Thailand Date: Location: Thursday 2 nd August 2018, 9am 12pm Health Intervention and Technology Assessment Program
More informationAccelerating the Introduction of Rotavirus Vaccines into GAVI-Eligible Countries
Accelerating the Introduction of Rotavirus Vaccines into GAVI-Eligible Countries Investment Case for GAVI Secretariat Submitted by PATH s Rotavirus Vaccine Program in collaboration with WHO and the US
More informationDEVELOPING A GLOBAL IMMUNIZATION STRATEGY
DEVELOPING A GLOBAL IMMUNIZATION STRATEGY 2021-2030 SAGE meeting, 18 October 2017 Carsten Mantel - Stefano Malvolti PERSPECTIVES ON SCENARIO 2021-2030 THE BROADER HEALTH ISSUES More frequent and more severe
More informationSAGE recommendations on non-specific effects of vaccines and their implementation
SAGE recommendations on non-specific effects of vaccines and their implementation Andrea Vicari Initiative for Vaccine Research Immunization, Vaccines and Biologicals Topics Process of developing immunization
More informationAnnotations to the provisional agenda
Technology Executive Committee 29 August 2017 Fifteenth meeting Bonn, Germany, 12 15 September 2017 Annotations to the provisional agenda 1. Opening of the meeting 1. The Chair of the Technology Executive
More informationTranslating Science to end HIV in Latin America and the Caribbean
Translating Science to end HIV in Latin America and the Caribbean Mexico City, Mexico, 17 th - 18 th and 21 st April www.iasociety.org IAS 2017 post-conference workshop, 17 April 2018 Challenges for PrEP
More informationDRUG AND ALCOHOL TREATMENT ACTIVITY WORK PLAN
DRUG AND ALCOHOL TREATMENT ACTIVITY WORK PLAN 2016-2019 1 Primary Health Networks Drug and Alcohol Treatment Activity Work Plan 2016-2019 Primary Health Tasmania t: 1300 653 169 e: info@primaryhealthtas.com.au
More informationModeling the public health impact of malaria vaccines for developers and policymakers
Nunes et al. BMC Infectious Diseases 2013, 13:295 RESEARCH ARTICLE Modeling the public health impact of malaria vaccines for developers and policymakers Julia K Nunes 1,9*, Vicky Cárdenas 1,2, Christian
More informationMeeting of the Polio Oversight Board (call) 1 September :00 am 11:00 am Meeting Minutes
Participants: Dr. Tom Frieden (CDC, POB Chair) Mr. John Germ (Rotary) Dr. Chris Elias (BMGF) Dr. Margaret Chan (WHO) Mr. Tony Lake (UNICEF) Meeting of the Polio Oversight Board (call) 1 September 2016
More informationMeeting report of the WHO Evidence Review Group on malaria burden estimation methods
Malaria Policy Advisory Committee Meeting 11 13 April 2018, Geneva, Switzerland Background document for Session 6 Meeting report of the WHO Evidence Review Group on malaria burden estimation methods 12
More informationINSTRUCTOR S NOTE. Copyright 2018, The Johns Hopkins University and Teaching Vaccine Economics Everywhere.
INSTRUCTOR S NOTE This case study can be used to motivate several learning objectives and can be tied to specific course objectives in the modules. In case studies the students are not spoon-fed. Instead,
More informationEvidence Review Group on MDA, MSAT and FSAT Malaria Policy Advisory Committee Geneva, Switzerland September 2015
Evidence Review Group on MDA, MSAT and FSAT Malaria Policy Advisory Committee Geneva, Switzerland 16-18 September 2015 Kevin Marsh Chairperson of the Evidence Review Group 1 Outline of the Presentation
More informationTaking vaccine effectiveness into public health decision making: The ProVac Example
http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz
More informationRotavirus Vaccine. Supply and Procurement Roadmap. The Market Shaping Goal. Public Summary. Rotavirus Supply and Procurement Roadmap UPDATE 2016
The Market Shaping Goal Shape markets for vaccines and other immunisation products to achieve moderate or high levels of healthy markets dynamics. Supply and Procurement Roadmap Rotavirus Vaccine Public
More informationFifth report of Committee A
SIXTY-EIGHTH WORLD HEALTH ASSEMBLY (Draft) A68/73 26 May 2015 Fifth report of Committee A (Draft) Committee A held its twelfth and thirteenth meetings on 25 May 2015 under the chairmanship of Dr Eduardo
More informationNew vaccine technologies: Promising advances may save more lives
New vaccine technologies: Promising advances may save more lives Vaccine Technology III June 10, 2010 PATH s vision A world where innovation ensures that health is within reach for everyone. 2 PATH s mission
More informationDr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya
Dr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya Presentation Outline Background Immunization Performance review Available Opportunities for engagement Planned and ongoing strategies- New
More informationehealth and Data Analytics Dementia Pathfinder Programme Dementia Analytics Research User Group (DARUG) PPI Steering Group
ehealth and Data Analytics Dementia Pathfinder Programme Dementia Analytics Research User Group (DARUG) PPI Steering Group Role Description & Terms of Reference August 2018 Role Description Project overview
More informationThe new CRP Portfolio: initial impressions from the ISPC Recalling the CRP evaluation process in Phase I SRF needs to give more direction
27 April 2016 The new CRP Portfolio: initial impressions from the ISPC The agenda for FC15 includes an item on the new portfolio. The purpose of this document is to remind the FC of the process that has
More informationReport of the First Meeting of the expert panel on health impact of Global fund investements
Geneva, 10 11 July 2014 Report of the First Meeting of the expert panel on health impact of Global fund investements 1/33 Contents Executive Summary... 3 Background... 4 Recommendations... 5 HIV... 5 TB...
More informationEconomic Evaluation. Introduction to Economic Evaluation
Economic Evaluation Introduction to Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationCross-cutting HSS (Health Systems Strengthening): Experience from WPRO
Cross-cutting HSS (Health Systems Strengthening): Experience from WPRO Momoe Takeuchi WHO WPRO/Health Services Development Kunhee Park WHO Lao PDR/MCH INTEGRATING RMNCH CONSULTANTS TRAINING FOR GLOBAL
More informationIntegrating the Patient Perspective Into Value Frameworks
Integrating the Patient Perspective Into Value Frameworks Avalere Health An Inovalon Company August, 2017 Speakers and Agenda Josh Seidman, PhD Senior Vice President jjseidman@avalere.com @jjseidman 1.
More informationChallenges and solutions in making evidence-based national vaccination policies and recommendations
Challenges and solutions in making evidence-based national vaccination policies and recommendations Philippe Duclos, WHO 15th ADVAC, Les Pensières, Veyrier du Lac, May 19, 2014 Developing evidence-based
More informationThe long-term clinical effectiveness of a community, one day, self-referral CBT workshop to improve insomnia: a 4 year follow-up
The long-term clinical effectiveness of a community, one day, self-referral CBT workshop to improve insomnia: a 4 year follow-up Background Insomnia is the most common mental health symptom in the UK and
More information